Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;16(9):e13601.
doi: 10.1111/1753-0407.13601.

Fasting blood glucose level and risk of all-cause and cause-specific mortality in peritoneal dialysis patients

So Jin Lim  1 , Ju Young Moon  1 , Kyung Hwan Jeong  1 , Gang Jee Ko  2 , Yun Jin Choi  3 , Hyeon Seok Hwang  1
Affiliations

Fasting blood glucose level and risk of all-cause and cause-specific mortality in peritoneal dialysis patients

So Jin Lim et al. J Diabetes. 2024 Sep.

Abstract

Background: Glycemic control is crucial in peritoneal dialysis (PD) patients with diabetes. Although fasting blood glucose (FBG) is the most commonly used index to measure blood glucose levels, there is currently no evidence supporting the association between FBG level and mortality risk in PD patients.

Methods: A total of 3548 diabetic PD patients between 2002 and 2018 were enrolled from the National Health Insurance Service database of Korea. We investigated the association between FBG levels and the risk of all-cause and cause-specific mortality.

Results: Patients with FBG levels 80-99 mg/dL exhibited the highest survival rates, whereas those with FBG levels ≥180 mg/dL had the lowest survival rates. Compared with FBG levels 80-99 mg/dL, the adjusted hazard ratios and 95% confidence interval for all-cause mortality significantly increased as follows: 1.02 (0.87-1.21), 1.41 (1.17-1.70), 1.44 (1.18-2.75), and 2.05 (1.73-2.42) for patients with FBG 100-124 mg/dL, FBG 125-149 mg/dL, FBG 150-179 mg/dL, and FBG ≥180 mg/dL, respectively. The risk for all-cause mortality also showed an increasing pattern in patients with FBG levels <80 mg/L. The risk of cardiovascular death significantly increased as FBG levels exceeded 125 mg/dL. However, the risk of infection-related and malignancy-related deaths did not show a significant increase with increasing FBG levels.

Conclusion: There was an increase in the risk of all-cause mortality as FBG levels exceeded 125 mg/dL in PD patients with diabetes, and the risk of cardiovascular death showed a strong correlation with FBG levels compared with other causes of death.

Keywords: all‐cause mortality; cause‐specific mortality; diabetes; fasting blood glucose; peritoneal dialysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier curves for mortality according to FBG levels. FBG, fasting blood glucose.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bell S, Fletcher EH, Brady I, et al. End‐stage renal disease and survival in people with diabetes: a national database linkage study. QJM. 2015;108(2):127‐134. doi:10.1093/qjmed/hcu170 - DOI - PMC - PubMed
    1. Collins AJ, Foley RN, Chavers B, et al. US Renal Data System 2013 annual data report. Am J Kidney Dis. 2014;63(1 Suppl):A7. doi:10.1053/j.ajkd.2013.11.001 - DOI - PubMed
    1. Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018;25(2):121‐132. doi:10.1053/j.ackd.2017.10.011 - DOI - PMC - PubMed
    1. Deshpande AD, Harris‐Hayes M, Schootman M. Epidemiology of Diabetes and Diabetes‐related complications. Phys Ther. 2008;88(11):1254‐1264. doi:10.2522/ptj.20080020 - DOI - PMC - PubMed
    1. Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash SK. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: an update on glucose toxicity. Biomed Pharmacother. 2018;107:306‐328. doi:10.1016/j.biopha.2018.07.157 - DOI - PubMed